Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
DXTK8N
|
||||
Drug Name |
N-{(S)-2-Cyclohexyl-1-[2-(4-methoxy-phenylamino)-ethylcarbamoyl]-ethyl}-4-[1,2,4]triazol-1-yl-benzamide
|
||||
Synonyms |
CHEMBL196673
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Formula |
C27H34N6O3
|
||||
Canonical SMILES |
COc1ccc(NCCNC(=O)[C@H](CC2CCCCC2)NC(=O)c3ccc(cc3)n4cncn4)cc1
|
||||
InChI |
InChI=1S/C27H34N6O3/c1-36-24-13-9-22(10-14-24)29-15-16-30-27(35)25(17-20-5-3-2-4-6-20)32-26(34)21-7-11-23(12-8-21)33-19-28-18-31-33/h7-14,18-20,25,29H,2-6,15-17H2,1H3,(H,30,35)(H,32,34)/t25-/m0/s1
|
||||
InChIKey |
KOLZVLRWUSMIPM-VWLOTQADSA-N
|
||||
Target and Pathway | |||||
Target(s) | Cathepsin K | Target Info | [1] | ||
Cathepsin L | Target Info | [1] | |||
KEGG Pathway | Lysosome | ||||
Osteoclast differentiation | |||||
Toll-like receptor signaling pathway | |||||
Rheumatoid arthritishsa04142:Lysosome | |||||
Phagosome | |||||
Antigen processing and presentation | |||||
Proteoglycans in cancer | |||||
Rheumatoid arthritis | |||||
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
RANKL Signaling Pathway | |||||
IL2 Signaling PathwayNetPath_16:IL4 Signaling Pathway | |||||
Reactome | Collagen degradation | ||||
Degradation of the extracellular matrix | |||||
Activation of Matrix Metalloproteinases | |||||
Trafficking and processing of endosomal TLR | |||||
MHC class II antigen presentationR-HSA-1236977:Endosomal/Vacuolar pathway | |||||
Assembly of collagen fibrils and other multimeric structures | |||||
MHC class II antigen presentation | |||||
WikiPathways | RANKL/RANK Signaling Pathway | ||||
Osteoclast SignalingWP2572:Primary Focal Segmental Glomerulosclerosis FSGS | |||||
References | |||||
REF 1 | URL: https://www.ebi.ac.uk/chembl/ The ChEMBL database in 2017 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.